A method for preparing a CSF-1R inhibitor or its acid salt

By using amine reagents such as morpholine or piperazine for condensation reactions in the preparation of CSF-1R inhibitors, the problems of low yield and high cost in existing technologies have been solved, and high-yield and high-purity CSF-1R inhibitors have been prepared, making them suitable for industrial production.

CN115385897BActive Publication Date: 2024-11-08ABBISKO THERAPEUTICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210564647.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-05-24
Filing Date
2022-05-23
Publication Date
2024-11-08
Estimated Expiration
2042-05-23

AI Technical Summary

Technical Problem

Existing methods for preparing CSF-1R inhibitors use expensive pyridine as an acid-binding agent, resulting in low yields and unsuitability for industrial production, making it difficult to meet the needs of clinical research and drug formulation.

Method used

The condensation reaction of compound (1) or its acid salt with compound (2) or its derivative in the presence of amine reagents, morpholine or piperazine is carried out to avoid the use of expensive pyridine, control the generation of impurities and improve the yield.

Benefits of technology

Achieving high yield and high purity of CSF-1R inhibitors, suitable for industrial production, with a yield nearly 3 times higher and purity up to 99.95%, meeting the needs of clinical research and pharmaceutical formulation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115385897B_ABST
    Figure CN115385897B_ABST
Patent Text Reader

Abstract

The present invention relates to a preparation method of a CSF-1R inhibitor or an acid salt thereof. The CSF-1R inhibitor has a compound structure of the following formula (A), and the CSF-1R inhibitor is prepared by a condensation reaction of 6-substituted-5-((2-(1-substituted-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine-2-amine and 3,3-disubstituted pyrrolidine-2-one-carbonyl chloride or a derivative thereof as raw materials in the presence of an amine reagent, morpholine or piperazine. The preparation method of the present invention is simple to operate, has a high yield in each step, and has a stable process, can meet the needs of industrial production, solves the problem of drug accessibility, and is conducive to accelerating the clinical development and drug marketing of CSF-1R inhibitors. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of drug synthesis, and specifically relates to a method for preparing a CSF-1R inhibitor or an acid salt thereof. Background Art

[0002] The full name of CSF-1R (cFMS) is colony stimulating factor-1 receptor. This receptor is a membrane protein expressed on the surface of macrophages and monocytes. Its extracellular segment can bind to macrophage colony stimulating factor, and the intracellular tyrosine kinase can activate the downstream cell growth and reproduction signaling pathways of macrophages and monocytes. Therefore, the CSF-1R signaling pathway has an important influence on the development and differentiation of macrophages and monocytes, as well as the physiological functions of tumor-associated macrophages (TAM). With the progress of tumor immunotherapy in recent years, tumor-associated macrophages (TAM) and myeloid-derived suppressor cells (MDSC) are considered to be directly related to the formation of the immunosuppressive microenvironment inside the tumor and the angiogenesis that supports tumor growth. At the same time, clinical studies have shown that the content of TAM is negatively correlated with the prognosis of tumor patients. In vivo efficacy experiments in mice have shown that inhibiting the CSF-1R signaling pathway can significantly reduce the number of macrophages that suppress the immune system inside the tumor and increase the content of CD8-positive T cells. These experimental results suggest that CSF-1R small molecule inhibitors may reverse the immunosuppressive environment within the tumor, promote the activation of the immune system, and prolong the lives of cancer patients.

[0003] In 2018, Shanghai Heyu Biopharmaceutical Co., Ltd. disclosed a series of compounds with selective CSF-1R inhibitory effects in WO2018214867A1, the general structural formula of which is as follows:

[0004]

[0005] This series of compounds is prepared from 3,3-disubstituted pyrrolidine-2-one-formyl chloride as raw material, and the compound of formula (A) is obtained through condensation reaction. The synthesis route is as follows:

[0006]

[0007] This step of the reaction uses expensive pyridine as an acid-binding agent, has a low yield of only 30.4%, and requires column chromatography, which is not conducive to industrial production. Therefore, it is urgent to develop a preparation method for the compound of formula (A) for industrial production and to prepare qualified APIs to meet the production needs of clinical research and marketed pharmaceutical preparations. Summary of the invention

[0008] The object of the present invention is to provide a method for preparing a CSF-1R inhibitor or an acid salt thereof, wherein the CSF-1R inhibitor is 3,3-disubstituted-N-(6-substituted-5-((2-(1-substituted-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxopyrrolidine-1-carboxamide, thereby meeting the production needs of clinical research and marketed pharmaceutical preparations.

[0009] The first aspect of the present invention provides a method for preparing a compound of formula (A) or an acid salt thereof, the method comprising the following steps: condensing a compound of formula (1) or an acid salt thereof with a compound of formula (2) or a derivative thereof to generate a compound of formula (A) or an acid salt thereof, wherein the condensation reaction is carried out in the presence of an amine reagent, morpholine or piperazine,

[0010]

[0011] in,

[0012] R1 and R2 are each independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 5-8 Aryl and 5-8 membered heteroaryl, or R1, R2 and the carbon atom to which they are directly connected together form a C 3-6 Cycloalkyl or 3-6 membered heterocyclic group, the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 5-8 substituted by aryl and 5-8 membered heteroaryl substituents;

[0013] R3 is selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, the above groups are optionally further substituted with one or more selected from deuterium, hydroxyl, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 1-4 Substituted by alkoxy, carboxyl and amino substituents;

[0014] R4 is selected from hydrogen, deuterium, C 1-4 Alkyl and C 3-6 Cycloalkyl, the above groups are optionally further substituted with one or more selected from deuterium, hydroxyl, halogen, cyano, C 1-4 Alkyl, C 3-6Cycloalkyl, 3-6 membered heterocyclic group, C 1-4 Substituted by alkoxy, carboxyl and amino substituents;

[0015] The "heterocyclic group" contains 1-2 heteroatoms selected from nitrogen atoms or oxygen atoms.

[0016] As a preferred embodiment, R1 and R2 are each independently selected from hydrogen, deuterium, hydroxyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclobutyl, cyclopentyl and phenyl; or, R1, R2 and the carbon atoms directly connected thereto together form cyclopropyl, cyclobutyl, cyclopentyl, morpholinyl, pyrrolyl, piperazinyl, oxetanyl or tetrahydrofuranyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, hydroxyl, methyl, trifluoromethyl, trideuteriomethyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclobutyl, cyclopentyl and phenyl;

[0017] R3 is selected from hydrogen, deuterium, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, morpholinyl, pyrrolyl, piperazinyl, oxetanyl and tetrahydrofuranyl, which are optionally further substituted with one or more substituents selected from deuterium, hydroxyl, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, morpholinyl, pyrrolyl, oxetanyl, tetrahydrofuranyl, methoxy, ethoxy, isopropoxy, carboxyl and amino;

[0018] R4 is selected from the group consisting of hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl, ethyl, isopropyl, cyclopropyl and cyclobutyl.

[0019] As a preferred embodiment, R1 and R2 are each independently selected from hydrogen, deuterium, hydroxyl, methyl, ethyl, methoxyethyl, n-propyl, isopropyl, methoxy, ethoxy, isopropoxy, benzyloxy, cyclopropyl, cyclobutyl, cyclopentyl and phenyl, or R1, R2 and the carbon atom directly connected thereto together form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, tetrahydrofuranyl or pyrrolyl group;

[0020] R3 is selected from hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl, methoxymethyl, hydroxymethyl, ethyl, methoxyethyl, hydroxyethyl, n-propyl, isopropyl, n-butyl, hydroxy-substituted isobutyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, morpholinyl, pyrrolyl, morpholinylethyl, methyl-substituted pyrrolyl, piperazinyl, oxetanyl, and tetrahydrofuranyl;

[0021] R4 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, trifluoromethyl and trideuteriomethyl.

[0022] As a preferred embodiment, the derivative of the compound of formula (2) is selected from the following compounds:

[0023]

[0024] Wherein, R1 and R2 are each independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 5-8 Aryl and 5-8 membered heteroaryl, or R1, R2 and the carbon atom to which they are directly connected together form a C 3-6 Cycloalkyl or 3-6 membered heterocyclic group, the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 5-8 The aryl group and the 5- to 8-membered heteroaryl group are substituted by substituents.

[0025] As a preferred embodiment, R1 and R2 are each independently selected from hydrogen, deuterium, hydroxyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclobutyl, cyclopentyl and phenyl; or, R1, R2 and the carbon atom to which they are directly connected together form cyclopropyl, cyclobutyl, cyclopentyl, morpholinyl, pyrrolyl, piperazinyl, oxetanyl or tetrahydrofuranyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, hydroxyl, methyl, trifluoromethyl, trideuteriomethyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclobutyl, cyclopentyl and phenyl.

[0026] As a preferred embodiment, R1 and R2 are each independently selected from hydrogen, deuterium, hydroxyl, methyl, ethyl, methoxyethyl, n-propyl, isopropyl, methoxy, ethoxy, isopropoxy, benzyloxy, cyclopropyl, cyclobutyl, cyclopentyl and phenyl, or, R1, R2 and the carbon atom to which they are directly connected together form cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, tetrahydrofuranyl or pyrrolyl.

[0027] As a preferred scheme, the feed ratio of the compound of formula (1) or its acid salt to the compound of formula (2) or its derivative is 1:(0.1-10); the preferred feed ratio is 1:(0.2-5), and the more preferred feed ratio is 1:(0.5-3).

[0028] As a preferred embodiment, the amine reagent is selected from methylamine, dimethylamine, ethylamine, diethylamine, propylamine, dipropylamine, tripropylamine, 1,2-dimethylpropylamine, cyclopropylamine, diisopropylamine, diisopropylethylamine, triethylamine, n-butylamine, isobutylamine, tert-butylamine, sec-butylamine, diisobutylamine, hexylamine, dicyclohexylamine, decylamine, dodecylamine, triethanolamine, 2-propyleneamine, ethanolamine, 3-propanolamine, isopropanolamine, diisopropanolamine, triisopropanolamine, dimethylethanolamine, diethylethanolamine, ethylenediamine, 1,3-propylenediamine, 1,4-butylenediamine, 1,5-pentanediamine or 1,6-hexanediamine.

[0029] As a preferred embodiment, the acid salt in the preparation method includes an inorganic acid salt or an organic acid salt.

[0030] As a further preferred embodiment, the inorganic acid salt is selected from hydrochloride, sulfate, hydrobromide, hydrofluoride, hydroiodide or phosphate.

[0031] As a further preferred embodiment, the organic acid salt is selected from acetate, dichloroacetate, trichloroacetate, trifluoroacetate, benzenesulfonate, p-toluenesulfonate, 4-chlorobenzenesulfonate, 1,5-naphthalene disulfonate, naphthalene-2-sulfonate, ethane-1,2-disulfonate, methanesulfonate, ethanesulfonate, benzoate, caprate, hexanoate, caprylate, cinnamate, citrate, cyclohexanesulfamic acid salt, camphorsulfonate, aspartate, camphorate, gluconate, glucuronate, glutamate, isoascorbate, lactate, malate, mandelate, pyroglutamate, tartrate, dodecyl sulfate, dibenzoyl tartaric acid or succinate.

[0032] As a preferred solution, the compound of formula (2) is prepared by the following steps: using the compound of formula (3) as a raw material to react to generate the compound of formula (2),

[0033] Wherein, R1 and R2 are as described for the compound of formula (A).

[0034] As a preferred solution, the compound of formula (2) is prepared in an acidic system, and the acidic system is an organic acid system. Preferably, the organic acid system is trimethylchlorosilane solution or ammonium chloride solution.

[0035] As a preferred solution, triphosgene and The reaction has a feed ratio of 1:(1-10), preferably, a feed ratio of 1:(1-6), and more preferably, a feed ratio of 1:(2-5), wherein R1 and R2 are as described for the compound of formula (A).

[0036] The second aspect of the present invention provides a compound of formula (A'),

[0037]

[0038] Wherein, R1 and R2 are as described for the compound of formula (A).

[0039] Preferably, the compound of formula (A") has the following structure:

[0040]

[0041] Compared with the prior art, the present invention has the following technical advantages:

[0042] 1. In terms of operation, the raw materials or reagents used in the present invention are simple and easy to obtain, the reaction conditions are mild, and the operability is strong. No column chromatography technology is used in the entire preparation process, which reduces the amount of reagents used, has little environmental pressure, and is suitable for industrial production.

[0043] 2. In terms of technology, the present invention uses common amine reagents, morpholine or piperazine, and unexpectedly finds that the acid binding agent can well control the generation of impurities during the reaction, and obtains a higher yield. In a specific embodiment, the inventors selected triethylamine and diisopropylethylamine as acid binding agents in the first and second step reactions, respectively, and well controlled the generation of impurities, obtained a yield of nearly 90%, and the purity was very high. Compared with the prior art with a yield of only 30%, the yield of the present invention has increased by nearly 3 times, which is suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 This is the HPLC spectrum of the compound of formula (A) obtained by reacting for two hours in the example preparation.

[0045] Figure 2 This is the HPLC spectrum of the final product of the compound of formula (A) prepared in Example. DETAILED DESCRIPTION

[0046] The inventors of the present application have developed a method for preparing 3,3-disubstituted-N-(6-substituted-5-((2-(1-substituted-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxopyrrolidine-1-carboxamide through extensive and in-depth research. The preparation method uses 3,3-dimethylpyrrolidine-2-one-carbonyl chloride or its derivatives as raw materials, and condenses the reaction in the presence of an amine reagent, morpholine or piperazine to prepare the 3,3-dimethylpyrrolidine-2-one-carbonyl chloride or its derivatives. The preparation method of the present invention is simple to operate, has a high yield in each step, and has a stable process. It can meet the needs of industrial production, solve the problem of drug accessibility, and is conducive to accelerating the clinical development and drug marketing of CSF-1R inhibitors. On this basis, the present invention was completed.

[0047] The present invention is further described in detail and completely below in conjunction with the embodiments, but the present invention is by no means limited to the contents of the embodiments.

[0048] The thin layer chromatography silica gel plate of the present invention uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate, and the specification adopted by TLC is 0.15mm-0.20mm.

[0049] The starting materials in the examples of the present invention are known and can be purchased on the market, or can be synthesized by or according to methods known in the art.

[0050] The purity of the compound of the present invention is detected by Agilent high performance liquid chromatography (HPLC). Chromatographic column: Waters C18. Mobile phase A: 0.05% trifluoroacetic acid in water, mobile phase B: 0.05% trifluoroacetic acid in acetonitrile. Flow rate: 1.0 mL / min. Detection wavelength: 245 nm.

[0051] Unless otherwise specified, the solvent is a dry solvent and the reaction temperature is in degrees Celsius (°C). Specific embodiments

[0053] Step 1: Synthesis of 3,3-dimethyl-2-carbonylpyrrolidine-1-carbonyl chloride

[0054]

[0055] Under nitrogen protection, dichloromethane (9.0L), 3,3-dimethylpyrrolidin-2-one (900.7g, 7.97mol), triethylamine (971g, 9.6mol) were added, cooled to -15°C, and trimethylsilyl chloride (1730g, 15.9mol) was added dropwise to the above mixture. Under nitrogen protection, triphosgene (778g, 2.6mol) was dissolved in dichloromethane (4.5L), cooled to -15°C, and 3,3-dimethylpyrrolidin-2-one mixture was slowly added to the triphosgene solution. After adding, the temperature was controlled at -15 to -25°C and stirred for half an hour, then the temperature was raised to 20 to 30°C and maintained for 1h, and the mixture was concentrated to dryness under reduced pressure, methyl tert-butyl ether was added to the residue, filtered and concentrated to obtain 1.35kg (purity: 74.3%) of 3,3-dimethyl-2-oxopyrrolidine-1-carbonyl chloride.

[0056] Step 2: Synthesis of 3,3-dimethyl-N-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxopyrrolidine-1-carboxamide

[0057]

[0058] Under nitrogen protection, add 2-methyltetrahydrofuran (115mL), 6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine (10.0g, 0.035mol), N,N-diisopropylethylamine (10.56g, 0.08mol), cool to 0°C, and add 3,3-dimethyl-2-oxopyrrolidine-1-carbonyl chloride in 2-methyltetrahydrofuran solution (10.20g, 0.058mol) dropwise to the above mixture. Heat to 20-30°C, stir and react for 2 hours (the HPLC spectrum of the reaction for two hours is attached). Figure 1 ), washed three times with 5.0% sodium bicarbonate solution, washed twice with saturated saline solution, concentrated the organic phase, added 12 mL of ethyl acetate, concentrated again to dryness, added ethyl acetate to the residue, filtered, and dried the filter cake to obtain 13.3 g of 3,3-dimethyl-N-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxopyrrolidine-1-carboxamide, (yield: 89.26%, purity: 99.95%, HPLC spectrum see attached Figure 2 )。 MS m / z(ESI):421[M+H] + .

[0059] 1H NMR (400MHz, DMSO-d6) δ11.02(s,1H),8.37(d,J=5.6Hz,1H),8.27(s,1H),7.98(s,1H),7.93(d,J=8.8Hz,1H),7.67(d,J=8.8Hz,1H),7 .19(d,J=2.5Hz,1H),6.62(dd,J=5.7,2.5Hz,1H),3.86(s,3H),3.78(t,J=7.0Hz,2H),2.28(s,3H),1.91(t,J=7.0Hz,2H),1.20(s,6H).

[0060] From the attached Figure 2 It can be seen that the target product 3,3-dimethyl-N-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxopyrrolidine-1-carboxamide has a liquid phase purity of up to 99.95%. There are only very small amounts of by-products in this reaction. After chromatographic analysis, the structures of the main impurity compounds are as follows:

[0061]

[0062] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as references separately. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope of the present invention.

Claims

1. A method for preparing a compound of formula (A) or an acid salt thereof, characterized in that: The preparation method comprises the following steps: The compound of formula (1) or its acid salt undergoes a condensation reaction with the compound of formula (2) or its derivative to generate the compound of formula (A) or its acid salt, wherein the condensation reaction is carried out in the presence of an amine reagent. Wherein, R1 and R2 are each independently selected from hydrogen, deuterium and methyl; R3 is selected from methyl, trifluoromethyl, trideuteriomethyl and ethyl; R4 is selected from hydrogen, deuterium and methyl; The amine reagent is diisopropylethylamine; The molar ratio of the compound of formula (1) or its acid salt to the compound of formula (2) or its derivative is 1:(0.1-10).

2. The preparation method according to claim 1, characterized in that: The derivatives of the compound of formula (2) are selected from the following compounds: Wherein, R1 and R2 are as described in claim 1.

3. The preparation method according to claim 1, characterized in that: The molar ratio of the compound of formula (1) or its acid salt to the compound of formula (2) or its derivative is 1:(0.2-5).

4. The preparation method according to claim 1, characterized in that: The molar ratio of the compound of formula (1) or its acid salt to the compound of formula (2) or its derivative is 1:(0.5-3).

5. The preparation method according to claim 1, characterized in that: The acid salt includes an inorganic acid salt or an organic acid salt; the inorganic acid salt is selected from hydrochloride, sulfate, hydrobromide, hydrofluoride, hydroiodide or phosphate; the organic acid salt is selected from acetate, dichloroacetate, trichloroacetate, trifluoroacetate, benzenesulfonate, p-toluenesulfonate, 4-chlorobenzenesulfonate, 1,5-naphthalene disulfonate, naphthalene-2-sulfonate, ethane-1,2-disulfonate, methanesulfonate, ethanesulfonate, benzoate, decanoate, hexanoate, caprylate, cinnamate, citrate, cyclohexanesulfamic acid salt, camphorsulfonate, aspartate, camphorate, gluconate, glucuronate, glutamate, isoascorbate, lactate, malate, mandelate, pyroglutamate , tartrate, dodecyl sulfate, dibenzoyl tartrate, formate, fumarate, galactonate, gentisate, acetohydroxamate, malonate, succinate, glutarate, adipate, sebacate, 2-ketoglutarate, glycolate, hippurate, isethionate, lactobionate, ascorbate, aspartate, laurate, maleate, nicotinate, oleate, orotate, oxalate, palmitate, pamoate, propionate, 4-acetamidobenzoate, 4-aminobenzoate, salicylate, 4-aminosalicylate, 2,5-dihydroxybenzoate, 1-hydroxy-2-naphthoate, stearate, thiocyanate, undecylenate, or succinate.

6. The preparation method according to claim 1, characterized in that: The compound of formula (2) is prepared by the following steps: using the compound of formula (3) as a raw material to react to generate the compound of formula (2), During the preparation of the compound of formula (2), triphosgene and The reaction has a feed molar ratio of 1:(1-10); wherein R1 and R2 are as described in claim 1.

7. The preparation method according to claim 6, characterized in that: The compound of formula (2) is prepared in an acidic system, wherein the acidic system is an organic acid system, and the organic acid system is a trimethylsilyl chloride solution or an ammonium chloride solution.

8. The preparation method according to claim 6, characterized in that During the preparation of the compound of formula (2), triphosgene and Reaction, the feeding mole ratio is 1: (1 ~ 6).

9. The preparation method according to claim 6, characterized in that: During the preparation of the compound of formula (2), triphosgene and The reaction has a feed molar ratio of 1:(2-5), wherein R1 and R2 are as described in claim 1.